Oura and LillyDirect Partner to Enhance Support for GLP-1 Therapy Users
Oura and LillyDirect recently announced a strategic collaboration. This partnership supports patients utilizing GLP-1 therapies. Furthermore, LillyDirect customers receive…
-
-
GLP-1 Weight Loss Drives New Demand for Laser Hair Removal
Significant weight loss from glucagon-like peptide-1 receptor agonists is changing how consumers behave in the aesthetic industry. Patients who…
-
GLP-1 Receptor Agonists in Older Adults: Why Aging Requires a Personalized Clinical Approach
Glucagon-like peptide-1 (GLP-1) receptor agonists and dual co-agonists have fundamentally transformed the management of type 2 diabetes and metabolic…
-
GLP-1 Drugs Show No Elevated Risk of Adverse Pregnancy Outcomes in First Trimester, Study Finds
A new medical study indicates that first-trimester GLP-1 receptor agonist exposure does not increase adverse pregnancy outcomes. Investigators published…
-
Intuitive Eating Explained: Learning to Trust Your Body’s Signals
Let’s be completely honest: diet culture is absolutely everywhere. For decades, society has told us that getting healthy means…
-
GLP-1 Drugs Reshape Consumer Markets as Appetite Suppression Drives Structural Demand Shifts
GLP-1 receptor agonists now impact markets far beyond their original medical uses. About 30 million people take these medications…
-
Myostatin Inhibitor Apitegromab Preserves Lean Mass During Tirzepatide-Induced Weight Loss in Phase 2 Trial
Myostatin Inhibitor Apitegromab Preserves Lean Mass During Tirzepatide-Induced Weight Loss in Phase 2 Trial Dual incretin mimetics like tirzepatide…
-
Mounjaro Emerges as Leading GLP-1 Therapy for Early-Stage Type 2 Diabetes
A recent company-funded clinical trial reveals that tirzepatide (Mounjaro) delivers superior glycemic control and weight loss compared to standard…
-
GLP-1 and Meal Replacements: The Perfect Combination for Weight Loss
Obesity is a major health issue in modern medicine. National data shows that about 42 percent of adults now…
-
GLP-1 Receptor Agonists Linked to Greater Physical Activity in MS; BLA Filed for Z-Rostudirsen; Ofatumumab Shows Superiority Over Rituximab in MOGAD
New data presented at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting indicate that glucagon-like peptide-1 receptor agonists…
